Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 813, pseudogene (RNU6-813P) is a non-coding RNA pseudogene related to U6 small nuclear RNA (snRNA). U6 snRNA is a core component of the major spliceosome complex, essential for pre-mRNA splicing in eukaryotic cells and highly conserved across species[1][3]. The RNU6-813P locus contains a nonfunctional copy (pseudogene) of the U6 snRNA gene sequence[2][7]. Unlike functional U6 snRNA genes, pseudogenes like RNU6-813P are generally not transcribed into functional RNA, or if transcribed, do not have known cellular roles in catalysis or regulation. They may result from duplication or retrotransposition events and may retain sequence similarity to functional U6 snRNA[5]. Although some pseudogenes can have regulatory effects through various mechanisms (such as acting as competing endogenous RNAs or antisense transcripts), there is no evidence that RNU6-813P has a known regulatory function, involvement in disease, or value as a therapeutic target[4][7]. This target is not a therapeutic macromolecule such as a receptor, enzyme, transporter, or transcription factor and should not be considered a "target" in the classical pharmacological or molecular sense. Its inclusion as a target is likely an error. Detailed context and clarifications: - GeneID and annotation: RNU6-813P is listed as a pseudogene in databases and lacks annotated protein-coding potential or associated biological processes or disease pathways[2][7]. - Canonical family/class: As a U6-derived pseudogene, it belongs in the broad family of small nuclear RNA (snRNA) pseudogenes[2][7]. - Functional note: Functional U6 snRNA participates in mRNA splicing within the spliceosome[1][3][11]. Pseudogenes of U6 do not encode functional snRNA and are typically considered genomic "fossils". - Pseudogene regulatory roles: While certain pseudogenes can act as miRNA sponges, antisense RNAs, or sources of small RNAs, these activities are not assumed for any given snRNA pseudogene without experimental evidence[4]. There are no data demonstrating RNU6-813P is active in this regard[7]. - Therapeutic targeting: Pseudogenes are not considered druggable targets, and no drugs, mechanisms of action, or biomarkers are linked to RNU6-813P. - Incorrectness: The target “RNU6-813P” is not suitable for assignment as a therapeutic target. Its inclusion likely stems from automated gene list extraction, not biological or pharmacological relevance. Summary for structured extraction: RNU6-813P (RNA, U6 small nuclear 813, pseudogene) is a genomic pseudogene of the U6 snRNA family with no established functional, therapeutic, or diagnostic relevance. Its inclusion as a target or druggable entity is incorrect; it serves no known biological or clinical function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 813, pseudogene (RNU6-813P).